Boehringer Ingelheim GmbH: PharmaVitae Profile

Publication Date	August 2008
Publisher	Datamonitor
Product Type	Report
Pages	106
ISBN Number	not applicable
Product Code	DAT13069

Price

£3,010.00
approximately: $4,398 | €3,299

PDF

PRINT £3,045 ($4,449 | €3,337)

Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Boehringer Ingelheim's performance against key rivals in the prescription pharmaceutical sector
Evaluate the impact of generic competition for the key product Flomax, particularly in light of recent patent expiry for another key product, Mobic
Assess how Boehringer could utilize externalization strategies to bolster its long term sales growth and support its internal product development

Content

CHAPTER 1 ABOUT THIS PROFILE
- Executive summary
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
- Data sourcing
- Sales data
- Analyst consensus
CHAPTER 2 EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales performance, 200113
- Financial performance, 200113
- Boehringer Ingelheim: PharmaVitae forecasts at a glance
- Strategic insight
- Leading position in core markets
- New launches struggle to match the decline of existing products
- External product deals needed to extend growth
- SWOT analysis
CHAPTER 3 QUARTERLY NEWS UPDATE
- Product developments
- Deals and alliances
- Product deals
- Technology deals
- M&A activity
- Company announcements
- Future product milestones
CHAPTER 4 COMPANY INTRODUCTION
- Key findings
- Background
- Current corporate structure
- Prescription pharmaceuticals
- Consumer healthcare
- Industrial customer
- Animal health
- M&A history
CHAPTER 5 COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 200113
- Product analysis
- Product analysis, 200107
- Product analysis, 200713
- Therapy area analysis
- Therapy area analysis, 200107
- Therapy area analysis, 200713
- Therapy area focus, 200113
- Geographic analysis
- Geographic analysis, 200107
- Geographic analysis, 200713
- Geographic focus, 200113
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 200713
- Core analysis, 200713
- Expiry analysis, 200713
- Launch/core/expiry configuration, 200713
- Molecule type analysis
- Molecule type analysis, 200107
- Molecule type analysis, 200713
- Externalization analysis
- Externalization analysis, 200107
- Externalization analysis, 200713
CHAPTER 6 COMPANY FINANCIALS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and company reported total sales, 200107
- Financial statements, 200107
- Profit and loss account, 200107
CHAPTER 7 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Respiratory
- Spiriva franchise
- Cardiovascular
- Micardis franchise
- Pradaxa
- Urology & gender specific health
- Flomax
- Central nervous system
- Sifrol/ Mirapex
CHAPTER 8 APPENDIX
- R&D pipeline
- References
- Abbreviations
- Exchange rates
TABLE OF TABLES
- Table 1: Boehringer Ingelheim: PharmaVitae forecasts at a glance
- Table 2: Boehringer Ingelheim key product developments, Q1 2008
- Table 3: Boehringer Ingelheim product deals and alliances, Q1 2008
- Table 4: Boehringer Ingelheim technology deals and alliances, Q1 2008
- Table 5: Boehringer Ingelheim M&A activity, Q1 2008
- Table 6: Boehringer Ingelheim company announcements, Q1 2008
- Table 7: Boehringer Ingelheim future product milestones, 200810
- Table 8: Boehringer Ingelheims major consumer healthcare products
- Table 9: Boehringer Ingelheim product portfolio overview ($m), 200107
- Table 10: Boehringer Ingelheim product portfolio overview ($m), 200713
- Table 11: Boehringer Ingelheim product portfolio overview ($m), 200107
- Table 12: Boehringer Ingelheim product portfolio overview ($m), 200713
- Table 13: Boehringer Ingelheim portfolio overview by geographic region ($m), 200107
- Table 14: Boehringer Ingelheim portfolio overview by geographic region ($m), 200713
- Table 15: Boehringer Ingelheim launch portfolio overview ($m), 200713
- Table 16: Boehringer Ingelheim core portfolio overview ($m), 200713
- Table 17: Boehringer Ingelheim expiry portfolio overview ($m), 200713
- Table 18: Boehringer Ingelheim portfolio overview by molecule type ($m), 200107
- Table 19: Boehringer Ingelheim product portfolio overview by molecule type ($m), 200713
- Table 20: Boehringer Ingelheim product portfolio overview by source ($m), 200107
- Table 21: Boehringer Ingelheim product portfolio overview by source ($m), 200713
- Table 22: Total Boehringer Ingelheim sales by business unit ($m), 200107
- Table 23: Boehringer Ingelheim profit and loss account ($m), 200107
- Table 24: Key products overview
- Table 25: Spiriva: overview
- Table 26: Spiriva: sales forecast ($m), 200713
- Table 27: Spiriva+salmeterol: sales forecast ($m), 200713
- Table 28: Micardis: overview
- Table 29: Micardis: sales forecast ($m), 200713
- Table 30: Micardis HCT: sales forecast ($m), 200713
- Table 31: Pradaxa: overview
- Table 32: Pradaxa: sales forecast ($m), 200713
- Table 33: Flomax: overview
- Table 34: Flomax: sales forecast ($m), 200713
- Table 35: Sifrol: overview
- Table 36: Sifrol: sales forecast ($m), 200713
- Table 37: Pramipexole ER: sales forecast ($m), 200713
- Table 38: Boehringer Ingelheims R&D pipeline (Phase Iregistration)
- Table 39: Exchange rates, 2007
- TABLE OF FIGURES
- Figure1: Boehringer Ingelheim prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
- Figure2: J&J operating revenue/cost analysis ($m), 200107
- Figure3: Boehringer Ingelheim prescription pharma sales by therapy area (% of total), 200113
- Figure4: Boehringer Ingelheim prescription pharmaceutical sales by product category ($m), 200113
- Figure5: Boehringer Ingelheim SWOT analysis
- Figure6: Current corporate structure
- Figure7: Boehringer Ingelheim prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
- Figure8: Boehringer Ingelheim key sales growth drivers and resistors ($m), 200107
- Figure9: Boehringer Ingelheim key sales growth drivers and resistors ($m), 200713
- Figure10: Boehringer Ingelheim prescription pharmaceutical sales by therapy area ($m), 200113
- Figure11: Boehringer Ingelheim prescription pharma sales by therapy area (% of total), 200113
- Figure12: Boehringer Ingelheim prescription pharmaceutical sales by geographic region ($m), 200113
- Figure13: Boehringer Ingelheim growth drivers and resistors by geographic region ($m), 200107
- Figure14: Boehringer Ingelheim drivers and resistors by geographic region ($m), 200713
- Figure15: Boehringer Ingelheim prescription pharmaceutical sales by geographic region (% of total), 200113
- Figure16: Boehringer Ingelheim launch/core/expiry configuration ($m), 200713
- Figure17: Boehringer Ingelheim prescription pharmaceutical sales by molecule type ($m), 200113
- Figure18: Boehringer Ingelheim growth drivers and resistors by molecule type ($m), 200713
- Figure19: Boehringer Ingelheim prescription pharmaceutical sales by source ($m), 200113
- Figure20: Boehringer Ingelheim growth drivers and resistors by source ($m), 200107
- Figure21: Boehringer Ingelheim growth drivers and resistors by source ($m), 200713
- Figure22: J&J operating revenue/cost analysis ($m), 200107